IKT (Inhibikase Therapeutics) Institutional Ownership: 92.69% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IKT Inhibikase Therapeutics Inc IKT
37 GF Score
Price $2.33
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Institutional Ownership?

Inhibikase Therapeutics IKT 37 Institutional Ownership is 92.69% as of Jul. 26, 2026. GuruFocus rates IKT with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Inhibikase Therapeutics's institutional ownership is 92.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Inhibikase Therapeutics's Insider Ownership is 5.12%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Inhibikase Therapeutics's Float Percentage Of Total Shares Outstanding is 68.20%.

Inhibikase Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics Institutional Ownership Chart

Inhibikase Therapeutics Historical Data

The historical data trend for Inhibikase Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 14.61 14.43 10.96 9.41 9.30 9.43 14.80 14.85 15.21 16.99
IKT
37GF Score
Inhibikase Therapeutics Inc IKT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 92.69% mean?
Inhibikase Therapeutics (IKT) has a Institutional Ownership of 92.69% as of Jul. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Institutional Ownership too high?
Inhibikase Therapeutics' current Institutional Ownership is 92.69%. Overall, Inhibikase Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Institutional Ownership compare to FHTX and OBIO?
Inhibikase Therapeutics' Institutional Ownership of 92.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Institutional Ownership is 92.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Institutional Ownership of 92.69%. The current Institutional Ownership is 92.69%. Inhibikase Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Institutional Ownership is 92.69% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
37GF Score

Get the complete analysis for IKT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price